You are here
- Home
- All Discontinued Products
AZD3355
Based on a review of phase II dose finding study results with the reflux inhibitor lesogaberan (AZD3355), a GABAB agonist under investigation for the treatment of gastroesophageal reflux disease, AstraZeneca has decided to terminate development of this compound.
- collapse Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France (REMAIN)
- collapse Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
- collapse A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
- collapse Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US (REMAIN)
- collapse Study to Compare Different Formulations of AZD3355
- collapse AZD3355 Dose-escalation Study in Healthy Males
- collapse TLESR-impedance Study in Patients
- collapse Drug Interaction Study Between AZD3355 and Nexium
- collapse Symptom Improvements in GERD Patients
- collapse Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms (C27)